Oncology Xagena
Bristol-Myers Squibb has announced long-term follow-up results ( median follow up of 20.3 months ) from the lung cancer cohort ( n=129 ) of the expanded Phase 1 dose-ranging study ( 003 ) of Nivolumab ...
Long-term follow-up results ( median follow up of 20.3 months ) from the lung cancer cohort ( n=129 ) of the expanded Phase 1 dose-ranging study ( study 003 ) of Nivolumab, an investigational PD-1 imm ...
Antiangiogenic agents Sunitinib ( Sutent ) and Pazopanib ( Votrient ) are SOC ( standard of care ) for metastatic renal cell carcinoma ( mRCC ), but new therapies are needed as patients advance throug ...
The majority of patients with non-small cell lung cancer ( NSCLC ) present at the time of diagnosis with advanced disease. Subsets of patients are eligible for therapies targeted at mutated oncogene d ...
The results from CheckMate -037, a phase 3 randomized, controlled open-label study of Nivolumab ( Opdivo ), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemothera ...
Researchers at the University of Texas MD Anderson Cancer Center in Houston, have found a link between microbes in the gut ( the microbiome ) and response to immunotherapy. In the study, the ability o ...
Updated data from the ongoing phase 1/2 ECHO-204 trial evaluating the safety and efficacy of Epacadostat, an oral selective IDO1 enzyme inhibitor, in combination with Nivolumab ( Opdivo ), a PD-1 immu ...
